While Cleven et al. showed that IDH1/2 mutations did not correlate with 5hmC loss or prognosis in central chondrosarcomas, their study did not directly assess the prognostic significance of 5hmC levels. This evidence concerns the gene IDH1 and chondrosarcoma.